AVITA Medical Inc
AVH: XASX (AUS)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
A$7.20 | Kvt | Fhtywqvv |
Avita Earnings: Costs Outpace Revenue Growth but Outlook Remains Strong
Fourth-quarter 2023 commercial revenue of USD 14.1 million was up a relatively soft 4% on the third quarter, but in line with our forecast. This was due to longer hospital approval timelines for certain customers that were previously flagged, and we still do not foresee this affecting Avita’s long-term opportunity.